Skip to main content
$1.62 $0.02 (0.9%)

12:05 PM EDT on 09/28/23

Cellectis (NASDAQ:CLLS)

CAPS Rating: 1 out of 5

Current Price $1.62 Mkt Cap $81.7M
Open $1.58 P/E Ratio -0.80
Prev. Close $1.60 Div. (Yield) $0.00 (0.0%)
Daily Range $1.58 - $1.62 Volume 5,075
52-Wk Range $1.58 - $4.04 Avg. Daily Vol. 50,517

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

55 Outperform
2 Underperform
 

All-Star Players

17 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CLLS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.94)
Submitted March 28, 2015

Cellectis is new to the Nasdaq and CAPS but it's an old friend to zzporte. Portefeuille originally began buying the stock below 5 in February 2014 and our gains on the stock since then are close to $50000. Portefeuille has a talent for spotting… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:CLLS Summary

Fools bullish on NASDAQ:CLLS are also bullish on:

Fools bearish on NASDAQ:CLLS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CLLS.

Recs

0
Member Avatar Darkstar1348 (< 20) Submitted: 1/4/2021 6:06:49 PM : Outperform Start Price: $27.97 NASDAQ:CLLS Score: -110.97

Founder led, first mover in allogeneic CAR-T therapy, best-in-class manufacturing, vast amount of patent-protected IP, strong partnerships.

Recs

0
Member Avatar bigfeetboy (< 20) Submitted: 8/25/2020 7:17:30 AM : Outperform Start Price: $18.50 NASDAQ:CLLS Score: -114.64

Feroldi rec

Recs

0
Member Avatar odocoileus (< 20) Submitted: 1/30/2020 11:54:10 PM : Outperform Start Price: $16.30 NASDAQ:CLLS Score: -122.50

CAR-T is an amazing idea. Like all amazing ideas, the devil is in the details. While taking someone's cells, bio-engineering them to recognize cancer cells, and putting them back in the body is crazy smart, the expense and the body's reaction to that process are limiting the success of this technology. While allogenic T-cells do not come from the patient's body, they have some advantages. Namely, price, convenience, safety, and speed. Whether they are as effective remains to be seen, but any effectiveness at all may give allogenic T-cells an advantage for first line use. I like both CLLS and ATRA in this arena. While CLLS broke a lot of ground, ATRA eventually surpassed them. Success in either should draw interest and money into this arena and the share price may see tandem benefits.

Leaderboard

Find the members with the highest scoring picks in CLLS.

Score Leader

TheFall2021

TheFall2021 (93.10) Score: +106.67

The Score Leader is the player with the highest score across all their picks in CLLS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
TheFall2021 93.10 1/21/2021 Underperform 5Y $31.89 -95.05% +11.63% +106.67 0 Comment
MergerMonday 40.41 10/18/2022 Underperform 3Y $2.49 -36.55% +14.44% +50.98 0 Comment
Jumpersfor < 20 6/11/2021 Outperform 5Y $15.38 -89.73% +1.22% -90.95 0 Comment
rspcorp 46.18 6/1/2021 Outperform 5Y $15.49 -89.80% +1.59% -91.39 0 Comment
imaghseham < 20 4/5/2021 Outperform 5Y $21.17 -92.54% +6.40% -98.94 0 Comment
foggs1 61.01 3/8/2021 Outperform 5Y $18.63 -91.52% +11.60% -103.12 0 Comment
Indavos < 20 2/16/2021 Outperform 3Y $27.02 -94.15% +8.97% -103.12 0 Comment
UnderdogIsHere < 20 2/25/2021 Outperform 5Y $20.82 -92.41% +11.54% -103.95 0 Comment
ennui 43.46 2/8/2021 Outperform 5Y $28.00 -94.36% +10.28% -104.64 0 Comment
jaltman 60.51 1/25/2021 Outperform 5Y $30.75 -94.86% +11.89% -106.75 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CLLS.